Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 839-846

  Carretero, Rafael ^a,b   Cabrera, Teresa ^a,b   Gil, Hernani ^a   Saenz Lopez, Pablo ^a,b   Maleno, Isabel ^a   Aptsiauri, Natalia ^a   Cozar, Jose M ^a   Garrido, Federico ^a,b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Dep Analisis Clinicos ^*  (Spain)

Author keywords

bladder; cancer; HLA; immunology; immunotherapy

Indexed keywords

BCG VACCINE; HLA ANTIGEN CLASS 1; MITOMYCIN;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELL SELECTION; CHROMOSOME 15; CHROMOSOME 6; CLINICAL ARTICLE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MICROSATELLITE MARKER; PRIORITY JOURNAL; TUMOR CELL; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79959705235     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25733     Document Type: Article

References (45)

1. Demkow T, Alter A, Wiechno P,. Intravesical Bacillus Calmette- Guérin therapy for T1 superficial bladder cancer. Urol Int 2008; 80: 74-9.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J,. EAU guidelines on non-muscle-carcinoma of the bladder. Actas Urol Esp 2009; 33: 361-71.
3. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA,. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56.
4. Jarvinen R, Kaasinen E, sankila A, Rintala E,. Long-term efficacy of maintenance Bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009; 56: 260-5.
5. Zlotta AR, Fleshner NE, Jewett MA,. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 2009; 3: 199-205.
6. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK,. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 1998; 26: 155-9. (Pubitemid 28305378)
7. Böhle A, Brandau S,. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-69. (Pubitemid 36999613)
8. Videira PA, Calais FM, Correia M, Ligeiro D, Crespo HJ, Calais F, Trindade H,. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009; 74: 944-50.
9. Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K, Matsuoka K,. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. Int J Oncol 2006; 29: 1555-60.
10. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y,. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009; 125: 1365-71.
11. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S,. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31: 849-57.
12. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T,. Correlation between tumour regression and T cell responses in melanoma patients vaccinated with MAGE antigen. Proc Natl Acad Sci USA 2004; 101: 14631-8. (Pubitemid 39346735)
13. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S,. Escape of human solid tumours from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
14. Garrido F, Algarra I,. MHC antigens and tumour escape from immune surveillance. Adv Cancer Res 2001; 83: 117-58. (Pubitemid 32959264)
15. Pawelec G,. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53: 262-274. (Pubitemid 38328050)
16. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F,. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-89. (Pubitemid 46109029)
17. Cabrera T, Pedrajas G, Cozar JM, Garrido A, Vicente J, Tallada M, Garrido F,. HLA class I expression in bladder carcinomas. Tissue Antigens 2003; 62: 324-7. (Pubitemid 37204586)
18. Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, Lõpez-Nevot MA, Garrido F,. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 2006; 58: 503-10 (Pubitemid 44025525)
19. Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, Sato N, Tsukamoto T,. Effect of human leukocyte antigen class I expression of tumour cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Cancer Res 2006; 12: 4641-4. (Pubitemid 44297816)
20. Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Sato N, Tsukamoto T,. Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci 2009; 100: 2331-4.
21. Cabrera T, Lara E, Romero JM, Maleni I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F,. HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination. Cancer Immunol Immunother 2007; 56: 709-17. (Pubitemid 46348739)
22. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T,. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008; 60: 439-47.
23. Barnstable CJ, Bodmer WF, Brown G, Galfre BB, Milstein C, Williams AF, Ziegler A, Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978; 14: 9-20. (Pubitemid 8340429)
24. Lampson LA, Fisher CA, Whelan JP,. Striking paucity of HLA-A, B, C and beta2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130: 2471-8. (Pubitemid 13086807)
25. Lopez-Nevot MA, Cabrera T, de la Higuera B, Ruiz-Cabello F, Garrido F,. Production and characterization of monoclonal antibodies against leukemic cells. Inmunología 1986; 5: 51.
26. Lozano F, Santos-Aguado J, Borche L, Places L, Domenech N, Gaya A, Vilella R, Vives J,. Identification of the aminoacid residues defining an intralocus determinant in the a1 domain of HLA-A molecules. Immunogenetics 1989; 30: 50-3. (Pubitemid 19182827)
27. Lozano F, Borche L, Places L, Alberola-Ila J, Gayá A, Vilella R, Vives J,. Biochemical and serological characterization of a public antigenic determinant present on HLA-B molecules. Tissue Antigens 1990; 35: 193-5. (Pubitemid 20168336)
28. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL,. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 113-25. (Pubitemid 20050409)
29. Garrido F, Cabrera T, Accolla RS, Bensa JC, Bodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, et al. In:, Charron D, ed. Genetic diversity of HLA: functional and medical implications. Paris: EDK, 1997. 1: 445.
30. Koene GJ, Arts-Hilkes YH, van der Ven KJ, Rozemuller EH, Slootweg PJ, de Weger RA, Tilanus MG,. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis. Tissue Antigens 2004; 64: 452-61. (Pubitemid 39312726)
31. Boon T, van der Bruggen P,. Human tumour antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-9. (Pubitemid 26113944)
32. Renkvist N, Castelli C, Robbins PF, Parmiani G,. A listing of human tumour antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 3-15. (Pubitemid 32250041)
33. Coulie PG, Hanagiri T, Takenoyama M,. From tumour antigens to immunotherapy. Int J Clin Oncol 2001; 6: 163-70.
34. Rosenberg SA,. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4. (Pubitemid 32467048)
35. Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42. (Pubitemid 35398863)
36. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4. (Pubitemid 35231542)
37. Rosenberg SA, Dudley ME,. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-40.
38. Rosenberg SA, Yang JC, Restifo NP,. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15. (Pubitemid 39273730)
39. Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G,. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 2005; 5: 463-6.
40. Zou W,. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74. (Pubitemid 40488632)
41. Seliger B,. Molecular mechanisms of MHC class I abnormalities and APM components in human tumours. Cancer Immunol Immunother 2008; 57: 1719-26.
42. Drake CG, Jaffee E, Pardoll DM,. Mechanism of immune evasion by tumours. Adv Immunol 2006; 90: 51-81.
43. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD,. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998. (Pubitemid 35363648)
44. Garrido F, Cabrera T, Aptsiauri N,. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int J Cancer 2010; 127: 249-56.
45. Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F,. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008; 57: 1727-33.